Company intelligence / Profile preview

Vivace Health

San Mateo, California, United Statesvivacehealth.com.au ↗

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

Vivace Therapeutics’ lead candidate, VT3989, has shown notable clinical activity in patients with refractory mesothelioma who have failed standard therapies. Over 150 patients have been dosed and evaluated. The company is preparing to advance VT3989 into a registrational Phase 3 trial based on encouraging safety and efficacy data from earlier studies. Results will be presented at a major medical conference in late 2025.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

RA Capital ManagementCanaan PartnersCenova CapitalWuXi Healthcare Ventures II

Beyond the preview

Go deeper on Vivace Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivace Health.

Explore the full profile